KR102116087B1 - 리카르바제핀 아세테이트를 포함하는 경구 투여형 - Google Patents

리카르바제핀 아세테이트를 포함하는 경구 투여형 Download PDF

Info

Publication number
KR102116087B1
KR102116087B1 KR1020187037643A KR20187037643A KR102116087B1 KR 102116087 B1 KR102116087 B1 KR 102116087B1 KR 1020187037643 A KR1020187037643 A KR 1020187037643A KR 20187037643 A KR20187037643 A KR 20187037643A KR 102116087 B1 KR102116087 B1 KR 102116087B1
Authority
KR
South Korea
Prior art keywords
disintegrant
granules
oral dosage
dosage form
acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187037643A
Other languages
English (en)
Korean (ko)
Other versions
KR20190000929A (ko
Inventor
테오필루 카르도수 데 바스콘셀로스
리마 리카르두 조르제 도스 산토스
코스타 루이 세르데이라 데 캠포스
Original Assignee
바이알 - 포르텔라 앤드 씨에이 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40254311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102116087(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이알 - 포르텔라 앤드 씨에이 에스에이 filed Critical 바이알 - 포르텔라 앤드 씨에이 에스에이
Publication of KR20190000929A publication Critical patent/KR20190000929A/ko
Application granted granted Critical
Publication of KR102116087B1 publication Critical patent/KR102116087B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187037643A 2007-10-26 2008-10-24 리카르바제핀 아세테이트를 포함하는 경구 투여형 Active KR102116087B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98279007P 2007-10-26 2007-10-26
US60/982,790 2007-10-26
PCT/PT2008/000043 WO2009054743A1 (en) 2007-10-26 2008-10-24 Oral dosage forms comprising licarbazξpine acetate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167036806A Division KR20170004034A (ko) 2007-10-26 2008-10-24 리카르바제핀 아세테이트를 포함하는 경구 투여형

Publications (2)

Publication Number Publication Date
KR20190000929A KR20190000929A (ko) 2019-01-03
KR102116087B1 true KR102116087B1 (ko) 2020-05-28

Family

ID=40254311

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187037643A Active KR102116087B1 (ko) 2007-10-26 2008-10-24 리카르바제핀 아세테이트를 포함하는 경구 투여형
KR1020167036806A Ceased KR20170004034A (ko) 2007-10-26 2008-10-24 리카르바제핀 아세테이트를 포함하는 경구 투여형
KR1020107011233A Ceased KR20100093057A (ko) 2007-10-26 2008-10-24 리카르바제핀 아세테이트를 포함하는 경구 투여형

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020167036806A Ceased KR20170004034A (ko) 2007-10-26 2008-10-24 리카르바제핀 아세테이트를 포함하는 경구 투여형
KR1020107011233A Ceased KR20100093057A (ko) 2007-10-26 2008-10-24 리카르바제핀 아세테이트를 포함하는 경구 투여형

Country Status (24)

Country Link
US (5) US8372431B2 (cg-RX-API-DMAC7.html)
EP (2) EP2214636B1 (cg-RX-API-DMAC7.html)
JP (4) JP2011500797A (cg-RX-API-DMAC7.html)
KR (3) KR102116087B1 (cg-RX-API-DMAC7.html)
CN (1) CN101848698A (cg-RX-API-DMAC7.html)
AR (1) AR069031A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008317584B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0818680B1 (cg-RX-API-DMAC7.html)
CA (1) CA2703313C (cg-RX-API-DMAC7.html)
CY (1) CY1118350T1 (cg-RX-API-DMAC7.html)
DK (1) DK2214636T3 (cg-RX-API-DMAC7.html)
ES (2) ES2607002T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20161329T1 (cg-RX-API-DMAC7.html)
HU (1) HUE030788T2 (cg-RX-API-DMAC7.html)
IL (1) IL205160A0 (cg-RX-API-DMAC7.html)
LT (1) LT2214636T (cg-RX-API-DMAC7.html)
MX (1) MX2010004323A (cg-RX-API-DMAC7.html)
PL (1) PL2214636T3 (cg-RX-API-DMAC7.html)
PT (2) PT2214636T (cg-RX-API-DMAC7.html)
RS (1) RS55376B1 (cg-RX-API-DMAC7.html)
RU (1) RU2546521C2 (cg-RX-API-DMAC7.html)
SI (1) SI2214636T1 (cg-RX-API-DMAC7.html)
UA (1) UA110012C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009054743A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
KR20120046753A (ko) 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
CA2769181C (en) 2009-07-27 2017-11-28 Bial-Portela & Ca., S.A. Use of 5h-dibenz / b, f/ azepine-5-carboxamide derivatives for treating fibromyalgia
AU2010313571B2 (en) 2009-10-26 2014-07-31 Merck Sharp & Dohme Llc Solid pharmaceutical compositions containing an integrase inhibitor
US20120121703A1 (en) * 2010-07-20 2012-05-17 Japan Tobacco Inc. Tablet containing ferric citrate
TR201008460A1 (tr) * 2010-10-15 2012-05-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Eslikarbazepinin saşe formülasyonları.
JP6133786B2 (ja) * 2010-12-31 2017-05-24 ビアル−ポルテラ エ コンパニア，ソシエダッド アノニマ エスリカルバゼピンアセテート含有顆粒
EP2747770A1 (en) 2011-08-26 2014-07-02 BIAL - Portela & Cª S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
EP3103444A1 (en) 2015-06-09 2016-12-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of lacosamide and eslicarbazepine
WO2017103876A1 (en) 2015-12-18 2017-06-22 Jubilant Generics Limited Solid oral dosage forms of eslicarbazepine
KR102280457B1 (ko) * 2016-06-29 2021-07-23 엘티디 "발렌타-인텔렉트" 메만틴 및 멜라토닌의 배합물을 함유하는 약제학적 조성물
CN106913550B (zh) * 2017-03-10 2019-12-17 扬子江药业集团北京海燕药业有限公司 一种醋酸艾司利卡西平片的制备方法
WO2019058354A1 (en) * 2017-09-25 2019-03-28 Jubilant Generics Limited SUSPENSION OF ESLICARBAZÉPINE
US11318145B2 (en) 2018-09-25 2022-05-03 Jubilant Generics Limited Eslicarbazepine suspension
EA037195B1 (ru) * 2018-03-28 2021-02-18 Акционерное Общество "Химфарм" Биологически активная добавка для улучшения функционального состояния дыхательной системы и восстановления иммунной системы (варианты)
US20220127567A1 (en) 2018-09-14 2022-04-28 Keio University Method for producing astrocytes
HUP1900153A1 (hu) 2019-05-14 2020-11-30 Meditop Gyogyszeripari Kft Eszlikarbazepin-acetát tartalmú granulátum, ennek elõállítása, ezt tartalmazó egyéb gyógyszerkészítmények, és ezek alkalmazása
WO2021226256A1 (en) * 2020-05-05 2021-11-11 Neurobo Pharmaceuticals, Inc. Niclosamide formulations and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) * 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
GB9721497D0 (en) * 1997-10-09 1997-12-10 Ciba Geigy Ag Organic compounds
JP2001526212A (ja) * 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション 咀嚼分散性錠剤の製造法
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
IN190699B (cg-RX-API-DMAC7.html) * 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
GB0111566D0 (en) * 2001-05-11 2001-07-04 Portela & Ca Sa Method for preparation of (s)-(+)-and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azephine-5-carboxamide
GB0112812D0 (en) * 2001-05-25 2001-07-18 Portela & Ca Sa Mthd for preparation of 10, 11-dihydro-10-hydroxy-5H-dibenz/B,F/azepine-5-c arboxamide and 10,11-dihydro-10-oxo-5H-dibenz/B,F/azepine-5-carb oxamide therefrom
WO2003075830A2 (en) * 2002-03-14 2003-09-18 Sun Pharmaceutical Industries Limited Oral controlled drug delivery system containing carbamazepine
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
EP1509207B1 (de) * 2002-05-31 2009-04-29 Desitin Arzneimittel GmbH Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
DE10230027A1 (de) 2002-07-04 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen auf der Basis von Natriumkanalblockern und Magnesiumsalzen
GB0221956D0 (en) 2002-09-20 2002-10-30 Novartis Ag Organic compounds
CA2497780A1 (en) 2002-10-17 2004-04-29 Novartis Ag Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
GB2401605A (en) * 2003-05-12 2004-11-17 Portela & Ca Sa Method for racemisation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and optically enriched mixtures thereof
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US7956140B2 (en) 2004-03-17 2011-06-07 Dsm Ip Assets B.V. Polymerization catalyst comprising amidine ligand
PE20051156A1 (es) 2004-03-22 2006-02-13 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
AR048672A1 (es) 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
GB2416167A (en) 2004-07-13 2006-01-18 Portela & Ca Sa Chiral inversion and esterification of (S)- and (R)-10-hydroxy-dibenzazepine carboxamides
EP2098223A1 (en) 2004-11-10 2009-09-09 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form
GB0425320D0 (en) * 2004-11-17 2004-12-22 Johnson Matthey Plc Diamines
GB2422149A (en) * 2005-01-14 2006-07-19 Portela & Ca Sa Process for the preparation of 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide
MX366496B (es) 2005-05-06 2019-07-11 Bial Portela & Ca Sa Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.
EP2380573B1 (en) 2005-05-06 2015-02-25 Bial-Portela & CA, S.A. Eslicarbazepine acetate and methods of use
US8059672B2 (en) 2005-05-18 2011-11-15 Sprint Communications Company L.P. Internet communications between wireless base stations and service nodes
US20070071819A1 (en) * 2005-05-30 2007-03-29 Kesarwani Amit K Multiple unit modified release compositions of carbamazepine and process for their preparation
WO2007008576A2 (en) 2005-07-08 2007-01-18 Taro Pharmaceuticals U.S.A., Inc. Oxcarbazepine formulation
GB0515690D0 (en) 2005-07-29 2005-09-07 Portela & Ca Sa Asymmetric catalytic reduction
WO2007029093A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of oxcarbazepine
US20070178164A1 (en) 2006-01-31 2007-08-02 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
CA2634879A1 (en) 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of oxcarbazepine and methods for its preparation
GB0603008D0 (en) 2006-02-14 2006-03-29 Portela & Ca Sa Method
GB2437078A (en) 2006-04-11 2007-10-17 Portela & Ca Sa 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives
WO2008037044A1 (en) 2006-09-27 2008-04-03 Medley S.A. Indústria Farmacêutica Oxcarbazepine-containing oral formulation and a process to obtain the same
US20080138403A1 (en) 2006-12-08 2008-06-12 Sun Pharmaceutical Industries Ltd. Pharmaceutical dosage forms of oxcarbazepine
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
WO2017103876A1 (en) 2015-12-18 2017-06-22 Jubilant Generics Limited Solid oral dosage forms of eslicarbazepine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) * 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use

Also Published As

Publication number Publication date
CN101848698A (zh) 2010-09-29
HRP20161329T1 (hr) 2016-12-02
IL205160A0 (en) 2010-11-30
US20140343043A1 (en) 2014-11-20
JP6043758B2 (ja) 2016-12-14
EP2214636A1 (en) 2010-08-11
CA2703313A1 (en) 2009-04-30
KR20170004034A (ko) 2017-01-10
US20210322436A1 (en) 2021-10-21
AU2008317584B2 (en) 2015-01-22
KR20100093057A (ko) 2010-08-24
US20170112850A1 (en) 2017-04-27
HUE030788T2 (en) 2017-06-28
AU2008317584A1 (en) 2009-04-30
UA110012C2 (uk) 2015-11-10
KR20190000929A (ko) 2019-01-03
CY1118350T1 (el) 2017-06-28
EP2214636B1 (en) 2016-09-28
LT2214636T (lt) 2016-11-25
JP2017014233A (ja) 2017-01-19
SI2214636T1 (sl) 2017-01-31
CA2703313C (en) 2017-03-07
US20090110722A1 (en) 2009-04-30
AR069031A1 (es) 2009-12-23
RS55376B1 (sr) 2017-03-31
RU2010121135A (ru) 2011-12-10
RU2546521C2 (ru) 2015-04-10
ES2898202T3 (es) 2022-03-04
EP3202392A1 (en) 2017-08-09
US10912781B2 (en) 2021-02-09
MX2010004323A (es) 2010-05-05
JP2014237658A (ja) 2014-12-18
PT2214636T (pt) 2016-12-20
ES2607002T3 (es) 2017-03-28
US9566244B2 (en) 2017-02-14
US8372431B2 (en) 2013-02-12
PT3202392T (pt) 2021-11-23
DK2214636T3 (en) 2017-01-16
JP2011500797A (ja) 2011-01-06
JP2018172407A (ja) 2018-11-08
US20130150348A1 (en) 2013-06-13
EP3202392B1 (en) 2021-08-25
BRPI0818680A2 (pt) 2017-05-02
WO2009054743A1 (en) 2009-04-30
PL2214636T3 (pl) 2017-02-28
BRPI0818680B1 (pt) 2022-05-24

Similar Documents

Publication Publication Date Title
US10912781B2 (en) Pharmaceutical composition comprising licarbazepine acetate
US20110014282A1 (en) Pharmaceutical composition for poorly soluble drugs
KR101468738B1 (ko) 경구 용량 형태
JP2010513356A (ja) ニューロキニンアンタゴニストを含む製剤
US20200222402A1 (en) A stable oral pharmaceutical composition of imatinib
US20060034911A1 (en) New oral immediated release dosage form
EP3250188A1 (en) Pharmaceutical composition comprising aprepitant and method for the preparation thereof
WO2019025934A1 (en) STABLE ORAL PHARMACEUTICAL COMPOSITION OF PIMAVANSERIN
TW202502353A (zh) 調配物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 11, Claim Number : 1, 2, 3, 5, 6, 8, 9, 10, 11, 12, 13, Period Limitation Text : 173, Comment Text : [] 31

PE0702 Decision to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G20-tex-PE0702

Protection beyond ip right term event data comment text: Claim Total Quantity : 11, Claim Number : 1, 2, 3, 5, 6, 8, 9, 10, 11, 12, 13, Period Limitation Text : 173, Comment Text : [] 31

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6